| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3034 |
| Trial ID | NCT05381662 |
| Disease | Acute Lymphoblastic Leukemia |
| Altered gene | CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Recruiting |
| Title | CD19 Chimeric Antigen Receptors and CD19 Positive Feeder T Cells as a Leukemia Consolidation Treatment |
| Year | 2022 |
| Country | China |
| Company sponsor | Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd |
| Other ID(s) | UCT19-T19 v1.1 |
| Cohort1: no lymphodepleting | |||||||||
|
|||||||||
| Cohort2: lymphodepleting | |||||||||
|
|||||||||